Related Experiment Videos
Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective
W J Wallis1, D E Furst, V Strand
1Virginia Mason Medical Center, Seattle, Washington, USA.
Rheumatic Diseases Clinics of North America
|August 26, 1998
Summary
Biotechnology advances are yielding promising biologic agents, including monoclonal antibodies and fusion proteins, for rheumatoid arthritis (RA) treatment. These therapies, moving from trials to regulatory approval, offer optimism for future RA management.
Area of Science:
- Rheumatology
- Biotechnology
- Immunology
Background:
- Rheumatoid synovitis understanding has advanced.
- Biotechnology has refined methods for therapeutic agent development.
Purpose of the Study:
- To review promising preclinical work on biologic agents for rheumatoid arthritis (RA).
- To discuss the potential role of biologics in future RA management.
Main Methods:
- Review of preclinical research on biologic agents.
- Analysis of therapeutic agents such as monoclonal antibodies and fusion proteins.
Main Results:
- Biologic agents show promise for RA treatment.
- Several agents are nearing federal regulatory approval.
Conclusions:
- Biologic therapies are expected soon for RA patients.
- There is optimism for the future of RA management with these advanced therapies.